The economic impact of ME/CFS: individual and societal costs.
Jason, Leonard A, Benton, Mary C, Valentine, Lisa et al. · Dynamic medicine : DM · 2008 · DOI
Quick Summary
This study looked at how much money ME/CFS costs both individual patients and society as a whole in the United States. Researchers examined medical bills, test costs, and medication expenses for ME/CFS patients in two different groups. They found that ME/CFS is very expensive—costing between $2,000 and $8,600 per patient per year in direct medical costs alone, and billions of dollars to society when you include lost work and productivity.
Why It Matters
This is one of the few U.S. studies quantifying ME/CFS's economic burden, providing concrete evidence of the substantial financial impact at both individual and societal levels. These findings support the need for increased research funding, better clinical recognition, and healthcare resource allocation for ME/CFS patients and services.
Observed Findings
Community sample: annual direct cost per patient of $2,342; total societal direct cost of approximately $2 billion
Tertiary sample: annual direct cost per patient of $8,675; total societal direct cost of approximately $7 billion
Combined direct and indirect costs: $18.7 billion (community sample) to $24.0 billion (tertiary sample) annually
Costs comprised office visits, medical tests, and medication expenses
Inferred Conclusions
ME/CFS imposes substantial economic burden regardless of recruitment source
Costs are significantly higher in tertiary (treatment-seeking) samples compared to community samples, suggesting variable disease severity and healthcare utilization
When indirect costs are included, ME/CFS represents a major public health economic concern
Despite affecting over 800,000 U.S. adults, economic impact of ME/CFS remains understudied relative to disease burden
Remaining Questions
How have direct and indirect costs of ME/CFS changed since 2008, and how do they compare to current prevalence estimates?
What accounts for the 3.7-fold difference in direct costs between community and tertiary samples—disease severity, healthcare access, or other factors?
What This Study Does Not Prove
This study does not establish the direct causes of ME/CFS or prove that high costs are due to any specific factor. It also does not account for indirect costs borne by patients themselves (such as lost wages or out-of-pocket expenses beyond insurance coverage), and the extrapolation to national figures relies on prevalence estimates that may not reflect current epidemiologic data.